Page 34 - 78_03

NOTICIAS
CIENTÍFICAS…

23.
Kruh,
N.
A.;
Rawat,
R.;
Ruzsicska,
B.
P.;
Tonge,
P.
J.;
(2007)
“Probing
mechanisms
of
resistance

to
the
tuberculosis
drug
isoniazid:
Conformational
changes
caused
by
inhibition
of
InhA,
the
enoyl

reductase
from
Mycobacterium
tuberculosis”,
Protein
Science,
16,
1617-­-1627.

24.
Vilcheze,
C.,
Weisbrod,
T.
R.;
Chen,
B.;
Kremer,
L.;
Hazbon,
M.
H.;
et
al.;
(2005)
“Altered

NADH/NAD+
ratio
mediates
coresistance
to
isoniazid
and
ethionamide
in
mycobacteria”,

Antimicrob.
Agents
Chemother.,
49,
708-­-720.

25.
Hartkoorn,
R.
C.;
Sala,
C.;
Neres,
J.;
Pojer,
F.;
Magnet,
S.;
Mukherjee,
R.;
Uplekar,
S.;
Boy-­-Röttger,

S.;
Altmann,
K.-­-H.;
Cole,
S.
T.;
(2012)
“Towards
a
new
tuberculosis
drug:
pyridomycin-­-nature’s

isoniazid”,
EMBO
Mol.
Med.,
4,
1-­-11.

26.
Glaziou,
P.;
Floyd,
K.;
Raviglione,
M.;
(2009)
“Global
burden
and
epidemiology
of
tuberculosis”,

Clin.
Chest
Med.,
30,
621-­-636.

27.
Maeda,
K.;
Kosaka,
H.;
Okami,
Y.;
Umezawa,
H.;
(1953)
“A
new
antibiotic,
pyridomycin”,
J.

Antibiot.,
7,
140.

28.
Shomura,
T.;
Amano,
S.;
Yoshida,
J.;
Kojima,
M.;
(1986)
“Dactylosporangiurn
fulvum
sp.
nov.”
Int.

J.
Syst.
Bacterial.,
166-­-169.

29.
Huang,
T.;
Wang,
Y.;
Yin,
J.;
Du,
Y.;
Tao,
M.:
et
al.;
(2011)
“Identification
and
Characterization
of

the
Pyridomycin
Biosynthetic
Gene
Cluster
of
Streptomyces
pyridomyceticus
NRRL
B-­-2517”,
J.
Biol.

Chem.,
286,
20648-­-20657.

30.
Cole,
S.
T.;
Brosch,
R.;
Parkhill,
J.;
Garnier,
T.;
Churcher,
C.;
Harris,
D.;
Gordon,
S.
V.;
Eiglmeier,

K.;
Gas,
S.;
Barry,
C.
E.;
et
al;
(1998)
“Deciphering
the
biology
of
Mycobacterium
tuberculosis
from

the
complete
genome
sequence”,
Nature,
393,
537-­-544.

31.
Lamichhane,
G.;
(2011)
“Novel
targets
in
M.
tuberculosis:
search
for
new
drugs”,
Trends
Mol.

Med.,
17,
25-­-33.

297